Several phase 3 trials utilizing TMZ for newly diagnosed IDHwt GBM showed that the median overall survival of patients with MGMT promoter-methylated IDHwt GBM was 21.2–23.2 months versus 14.0-15.3 months for patients with unmethylated IDHwt GBM [1, 14, 47, 48]. Here, MGMT is linked to glioblastoma.